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Background and purpose: Impaired bulbar functions of speech and swallowing
are among the most serious consequences of amyotrophic lateral sclerosis
(ALS). Despite this, clinical trials in ALS have rarely emphasized bulbar func-
tion as an endpoint. The rater-administered Amyotrophic Lateral Sclerosis
Functional Rating Scale-Revised (ALSFRS-R) or various quality-of-life mea-
sures are commonly used to measure symptomatic benefit. Accordingly, we
sought to evaluate the utility of measures specific to bulbar function in ALS.
Methods: We assessed bulbar functions in 120 patients with ALS, with clini-
cians first making direct observations of the degree of speech, swallowing and
salivation impairment in these subjects. Clinical diagnosis of bulbar impair-
ment was then compared with ALSFRS-R scores, speech rate, time to swallow
liquids and solids, and scores obtained when patients completed visual analog
scales (VASs) and the newly-developed 21-question self-administered Center
for Neurologic Study Bulbar Function Scale (CNS-BFS).
Results: The CNS-BFS, ALSFRS-R, VAS and timed speech and swallowing were
all concordant with clinician diagnosis. The self-report CNS-BFS and ALSFRS-R
bulbar subscale best predicted clinician diagnosis with misclassification rates of
8% and 14% at the optimal cut-offs, respectively. In addition, the CNS-BFS
speech and swallowing subscales outperformed both the bulbar component of
the ALSFRS-R and speech and swallowing VASs when correlations were made
between these scales and objective measures of timed reading and swallowing.
Conclusions: Based on these findings and its relative ease of administration,
we conclude that the CNS-BFS is a useful metric for assessing bulbar function
in patients with ALS.
Introduction
Impaired bulbar functions are among the most serious
of the consequences of amyotrophic lateral sclerosis
(ALS) and account for a disproportionate amount of
the disability that accompanies the disease [1,2]. The
brunt of the pathologic process is borne by large motor
neurons in the spinal cord, brainstem, motor cortex
and pyramidal tracts. As a result, patients experience
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inexorable paralysis of skeletal muscle, including the
tongue and pharyngeal muscles. This results in varying
degrees of impairment of bulbar functions, including
speech and swallowing, which is dictated by the extent
of lower and upper motor neuron involvement. Either
directly or indirectly, bulbar dysfunction affects sur-
vival [3]. For example, aspiration often occurs as a
result of dysphagia, acutely causing respiratory arrest
or leading to aspiration pneumonia. Additionally,
weight loss is a consequence of impaired swallowing
and is a negative predictive factor for survival [4]; it
may accelerate muscle wasting, which is a hallmark of
ALS.
Almost all clinical trials in ALS have employed the
Amyotrophic Lateral Sclerosis Functional Rating
Scale-Revised (ALSFRS-R) as the primary outcome
measure [5]. It is a 12-item rater-administered ordinal
scale that assesses function in four domains: bulbar
function, fine motor function, gross motor function
and respiration. The three items related to bulbar
function query abnormalities in speech, swallowing
and salivation. The ALSFRS-R has been shown to
correlate with changes in strength over time as well as
quality-of-life measures and it can predict survival [6].
However, the sensitivity of the bulbar function sub-
scales in detecting modest changes or a specific effect
of treatment has never been determined. Thus, a sensi-
tive measure of bulbar dysfunction would be of great
value, especially in the evaluation of a therapy aimed
at impacting speech and/or swallowing.
Although not commonly employed in clinical trials,
both the Norris and Appel scales have also been uti-
lized to track disease progression in clinical and
research settings [7,8]. More recently, researchers have
begun to focus on other means, some of them more
objective, for quantitating bulbar function. Instrumen-
tation-based approaches are being developed to ana-
lyze function across the four speech subsystems, with
aerodynamic pressure-flow and acoustic methods used
to assess the respiratory, phonatory and resonatory
subsystems, and three-dimensional motion-tracking
techniques used to measure the articulatory subsystem
[9]. Electrical impedance myography, a technique
involving the application of low-intensity, high-fre-
quency current to a muscle, has been employed to
longitudinally assess the extent of skeletal and tongue
muscle function in patients with ALS [10,11]. Fiberop-
tic endoscopy, an alternative to videofluoroscopy [12],
can be utilized to document impaired swallowing sec-
ondary to pharyngeal dysfunction. More recently,
transcranial magnetic stimulation has been used to
map the cortical representation of the swallowing
musculature [13] and could potentially be used in
patients with ALS to evaluate cortical changes in
swallow representation and excitability following ther-
apeutic interventions. Although promising, many of
these newer techniques are difficult to implement in a
clinical or research setting. It is relevant to this discus-
sion, as noted by Green et al. in 2013 [14], that “no
standardized diagnostic procedure for assessing bulbar
function in ALS exists” and “adequate markers of
bulbar dysfunction have yet to be identified.”
Although a protocol for assessing bulbar function
was recently published [9], we thought it important to
determine the utility of this instrument in a research
setting. Historically, ALS trials have emphasized sur-
vival. On a background of failed trials, Nuedexta has
been shown to improve speech and swallowing in a
double-blind treatment trial [15]. The endpoint of this
Phase 2 study was a self-report scale [Center for Neu-
rologic Study Bulbar Function Scale (CNS-BFS)] that
proved to be more sensitive to a treatment effect than
commonly used measures, such as timed speech and
swallowing. This compelled us to critically review the
tools available for the assessment of bulbar function,
ultimately leading us to conclude that self-report data
are a critical adjunct to the diagnostic armamentarium
in ALS clinical trials. This report summarizes the evi-
dence that supports this conclusion, a realization that
is consonant with new Food and Drug Administration
guidelines on the value of patient report outcome
measures in clinical trials. From the outset, this has
been our bias as the CNS Lability Scale, a self-report
tool for assessing emotional lability that we previously
developed [16–19], has proven to be a robust endpoint
in four clinical trials.
Methods
A total of 120 patients with ALS with bulbar impair-
ment were assessed at seven participating research sites.
Sixty of the subjects were representative of patients
attending a general ALS clinic. The remaining subjects
were participants in a double-blind, Phase 2 crossover
treatment trial to test the efficacy of Nuedexta in palli-
ating impaired bulbar function (NCT01806857) [15].
The demographic characteristics of the study popula-
tion were typical of patients with ALS seen in the USA
(i.e. average age of onset 57.9  11.0 years; 64% male
and 36% female; 95.8% Caucasian). The trial was
approved by the institutional review boards (IRBs) of
each site (Cleveland Clinic Foundation IRB, Provi-
dence Health and Services IRB, Hennepin County
Medical Center IRB, Sutter Health IRB, Mercy Health
IRB, Georgetown University IRB and the combined
IRB of Bryan LGHMedical Center and Saint Elizabeth
Regional Medical Center). All participants provided
written informed consent.
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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A clinical observer made a diagnosis of impaired
speech, swallowing and salivation through direct
observations of the subjects. To evaluate speech, par-
ticipants were instructed to read ‘The Rainbow Pas-
sage’, a commonly used paragraph employed by
speech–language pathologists to objectively assess
speech rate (words/min). Clinicians separately evaluated
speech as normal or abnormal with respect to loudness,
nasality and intelligibility. Speech was judged abnormal
if any of these characteristics were abnormal.
Objective measures of swallowing performance were
obtained. To evaluate the swallowing of liquids, partici-
pants were instructed to drink 30 mL of water from a
cup; assistance with holding the cup was provided to
those unable to hold it on their own. The total swallow
duration [time between lip closure and swallow (in s)]
was recorded for three trials. The average of the two
shortest swallows served as an objective measure of liq-
uid swallowing. To evaluate the swallowing of solids,
participants were instructed to eat one tablespoon of
cereal containing five Cheerios. The time to chew and
swallow the cereal [from lip closure to swallow (in s)]
from each of three trials was taken as an objective mea-
sure of solid swallowing. The inter- and intra-assessor
reliability of this measure is very high (intraclass corre-
lation coefficient, 0.98; P < 0.001) [20]. Clinicians sepa-
rately rated swallowing as normal or abnormal with
respect to choking, spillage and effort. Swallowing was
judged abnormal if any of these three characteristics
were abnormal.
Clinicians rated salivation as normal or abnormal
by observing drooling and dabbing during unstimu-
lated and stimulated conditions. ‘Unstimulated’ saliva-
tion was determined over 10–15 min during which
time the subjects completed the self-report scales.
‘Stimulated’ salivation was assessed while the subjects
read the test paragraph and performed the timed
swallowing studies. Salivation was judged as abnormal
if either drooling or dabbing occurred in either the
unstimulated or stimulated state. An overall clinician
diagnosis of bulbar function was scored as abnormal
if any of the speech, swallowing or salivation domains
were judged to be impaired.
After completing the objective tests, subjects com-
pleted the self-administered 21-question CNS-BFS and
visual analog scales (VASs) for speech, swallowing and
salivation. A trained evaluator scored the ALSFRS-R.
The CNS-BFS is structured to interrogate three
domains of bulbar function: speech, swallowing and
salivation. For each domain, subjects are asked to rate
seven statements or questions on a scale of 1–5. (Sub-
jects who are unable to speak are assigned a value of
6 for each item comprising the speech domain.) Scores
can range from a low of 21 (no symptoms of bulbar
dysfunction) to a high of 112. In a clinical setting, an
evaluator provides instructions for completion of the
form by reference to a sample question. In essence,
the scale can be considered to be a quality-of-life mea-
sure. For example, six of the seven questions in the
swallowing domain of the CNS-BFS interrogate feed-
ing behaviors. The complete instrument as presented
to patients is illustrated in Fig. 1.
Relationships between clinician diagnosis of speech,
swallowing and salivation impairment, and each asso-
ciated measure (CNS-BFS, VAS and ALSFRS-R)
were evaluated by logistic regression. The strength of
association was summarized as area under the recei-
ver-operating characteristic curve (ROC AUC) and by
five measures (sensitivity, specificity, positive and neg-
ative predictive value, and total accuracy), each evalu-
ated at the threshold value that maximized the sum of
sensitivity and specificity (equivalent to maximizing
Youden’s index). Relationships among the continuous
measures were evaluated by Pearson correlations.
Factor structure of the 21 questions comprising the
CNS-BFS was examined by confirmatory factor anal-
ysis of the inferred polychoric correlations for both a
unidimensional scale and a three-factor structure that
associated each group of questions with its own
domain. Goodness of fit was assessed based on root
mean square error of approximation (RMSEA) and
Bentler’s Comparative Fit Index (CFI), with
RMSEA < 0.06 and CFI > 0.90 considered evidence
of adequate conformity to the tested factor structure.
We estimated the natural rate of progression of the
CNS-BFS total score and alternative measures of bul-
bar function using a random-slopes linear mixed
model. The model included an intercept and a fixed
effect of time and random participant-specific inter-
cepts and slopes with unstructured covariance. To
estimate natural rate of progression unaffected by
treatment, only data from observation times when a




The CNS-BFS total score and ALSFRS-R bulbar
subscale were highly predictive of clinician diagnosis
of impaired bulbar function (ROC AUC, 0.95 and
0.92, respectively; P < 0.001). CNS-BFS subscales also
predicted corresponding clinician diagnoses of speech,
swallowing and salivation impairment (ROC AUC,
0.83–0.95; P < 0.001) (Table 1).
Cutting scores for the identification of impaired bul-
bar function were designated and categorizations
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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CENTER FOR NEUROLOGICAL STUDY – BULBAR FUNCTION SCALE
Status: Done Not Done
Form Completed by: Subject Person other than subject
Date Performed: ___ ___/___ ___/___ ___ ___ ___
M    M    D    D    Y    Y    Y     Y
INSTRUCTIONS
The purpose of this questionnaire is to help us better understand your neurologic problems.  Please read 
each statement, and using the scale below, determine the degree to which it has applied to you DURING 
THE PAST WEEK.  Circle the appropriate answer, or if you need help in marking your responses, tell 














1 2 3 4 5
SIALORRHEA











1. Excessive saliva is a concern to me. 1 2 3 4 5
2. I take medication to control drooling.
1 2 3 4 5
3. Saliva causes me to gag or choke.
1 2 3 4 5
4. Drooling causes me to be frustrated or 
embarrassed. 1 2 3 4 5
5. In the morning I notice saliva on my 
pillow. 1 2 3 4 5
6. My mouth needs to be dabbed to 
prevent drooling. 1 2 3 4 5
7. My secretions are not manageable.
1 2 3 4 5
Figure 1 Center for Neurologic Study Bulbar Function Scale self-report scale.
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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based on these scores were compared with neurolo-
gists’ diagnoses for the purpose of examining criterion
validity. For example, a CNS-BFS score of 39
detected impaired bulbar function with a sensitivity of
91% and a specificity of 93%.
At a CNS-BFS score of 43, the scale detected
impaired bulbar function with a positive predictive
value of 98% in our sample (Table 2). In a research
setting, a score of 43 and above might be useful as an
inclusion criterion to select subjects who are most
likely to have the condition under treatment.
Construct validity
The self-report CNS-BFS total score was highly cor-
related with the bulbar subscale of the ALSFRS-R
(r = 0.90; P < 0.001). The CNS-BFS subscales for
speech, swallowing and salivation were better corre-
lated with the corresponding VAS scores than were
individual ALSFRS-R bulbar function questions.
Further, the CNS-BFS speech and swallowing sub-
scales were better correlated with speech rate and
timed swallowing of liquids and solids than were
SPEECH
Please circle the number that describes the degree to which each item has applied to you DURING THE PAST WEEK.
 Unable to communicate by speaking (score each item as 6)
Does not 
Apply Rarely Applies






1.  My speech is difficult to understand.
1 2 3 4 5
2.  To be understood I repeat myself.
1 2 3 4 5
3.  People who understand me tell other 
people what I said. 1 2 3 4 5
4.  To communicate I write things 
down or use devices such as a 
computer. 1 2 3 4 5
5.  I am talking less because it takes so 
much effort to speak. 1 2 3 4 5
6.  My speech is slower than usual.
1 2 3 4 5
7.  It is hard for people to hear me.
1 2 3 4 5
Figure 1 (Continued)
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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the ALSFRS-R or VAS speech and swallowing
scores.
Correlations of longitudinal change in these mea-
sures among the subset of participants followed in the
trial were weaker but largely paralleled the correla-
tions observed at baseline, with significant correlation
between changes in CNS-BFS total score and
ALSFRS-R bulbar subscore (Table 3).
Factor structure
Confirmatory factor analysis suggested a weak fit to a
unidimensional structure (RMSEA, 0.20; CFI, 0.63)
or a three-domain structure (RMSEA, 0.16; CFI, 0.77)
as originally conceived. Although the presumed factor
structure was weakly supported, Cronbach’s a sug-
gested strong internal consistency of the CNS-BFS,
with a coefficient of 0.939 for the speech subscale,
0.863 for the swallowing subscale, 0.862 for the sialor-
rhea subscale and 0.949 for the 21-question total
score.
This compared favorably with the ALSFRS-R bul-
bar subscale (0.837). The ALSFRS-R has historically
been regarded as the gold standard for assessing func-
tion in ALS clinical trials.
Test–retest reliability
The CNS-BFS total scores showed a test–retest relia-
bility over the 2-week screening interval of 0.86 [95%
confidence interval (CI), 0.80–0.93].
Sensitivity to natural progression
Up to 10 weeks of untreated follow-up, the ALSFSR-
R total score declined at an average rate of 1.1
SWALLOWING
Please circle the number that describes the degree to which each item has applied to you DURING THE PAST WEEK.









Applies Most of 
the Time
1.  Swallowing is a problem. 1 2 3 4 5
2.  Cutting my food makes it easier 
to chew and swallow. 1 2 3 4 5
3.  To get food down I have switched 
to a soft diet. 1 2 3 4 5
4.  After swallowing I gag or choke. 1 2 3 4 5
5.  It takes longer to eat. 
1 2 3 4 5
6.  My weight is dropping because I 
can’t eat normally. 1 2 3 4 5
7.  Food gets stuck in my throat.
1 2 3 4 5
Evaluator’s Initials: _____ ______ ______ Total: __________
Figure 1 (Continued)
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points/month (95% CI, 1.6 to 0.6), consistent with
previously published data from prior clinical trials in
ALS (Table 4). The ALSFRS-R bulbar subscore
declined at an average rate of 0.38 points/month
(95% CI, 0.59 to 0.17) out of a total 12-point
range. The CNS-BFS total score increased at an aver-
age rate of 1.2 points/month (95% CI, 0.1–2.2). This
was attributable to changes in speech (0.54; 95% CI,
0.05–1.03) and salivation (0.63; 95% CI, 0.11–1.16)
with minimal change observed in swallowing (0.03;
95% CI, 0.49 to 0.55). Clarifying this further, the
lack of change in swallowing was still evident when
restricting evaluation to participants first randomized
to placebo, with no demonstrable change in swallow-
ing over the first 6-week interval as measured by both
the CNS-BFS and ALSFRS-R. Similarly, the recently
developed self-report EAT-10 scale does not track well
over time (https://f1000research.com/posters/5-2856).
Sensitivity to intervention
Although it may not be relevant for future studies
involving other therapeutic interventions, we thought
it noteworthy to determine which domains of the
CNS-BFS and ALSFRS-R bulbar subscale were sensi-
tive to change following treatment with Nuedexta.
Both the speech domains of the CNS-BFS and the
ALSFRS-R bulbar scale were sensitive measures of a
treatment effect (P = 0.002 and <0.001, respectively).
In contrast, the swallowing and salivation domains of
the CNS-BFS were both responsive to treatment
(P = 0.007 and 0.005, respectively) whereas this was
not the case in the instance of the swallowing or
salivation questions of the ALSFRS-R (P = 0.80 and
P = 0.066, respectively), recognizing that P > 0.05 is
not evidence of lack of an effect. Among all the other
measures (timed speech and swallowing, and VAS for
speech, swallowing, and salivation), only the VAS for
speech was sensitive to treatment with Nuedexta
(P = 0.005).
Discussion
The assessment of bulbar function presents a challeng-
ing conundrum in clinical and research settings.
Unlike the evaluation of skeletal muscle, which is rela-
tively straightforward, bulbar function assessment is
more nuanced and not easily measured in the clinic.
In both settings, a number of factors are at play: cost,
convenience, reproducibility, subjective versus objec-
tive readouts, standardization and the issue of inter-
rater reliability. In an effort to shed light on this sub-
ject, we have undertaken an extensive evaluation of
the utility of measures employed in clinical trials to
assess bulbar function.
We initially compared each of these measures
against the clinician diagnosis of impaired bulbar
function. From our viewpoint, this is the best stan-
dard against which all other measures should right-
fully be compared. It is reassuring that all of these
measures (i.e. CNS-BFS, ALSFRS-R, VAS and timed
speech and swallowing) compared favorably with clin-
ician diagnosis. However, as observed, the self-report
CNS-BFS and the ALSFRS-R were better predictors
of clinician diagnosis than any other measures
(Table 1). Moreover, the recently developed CNS-BFS
Table 1 Criterion validity: prediction of clinician diagnosis of impaired function by individual measures of bulbar assessment
Measure 1 n
Full ROC curve Cut-off at maximum Youden’s index
AUC Lower Upper P-value Value Accuracy PPV NPV Sensitivity Specificity
CNS-BFS total score 112 0.954 0.915 0.993 <0.001 ≥39.0 0.920 0.955 0.870 0.913 0.930
CNS-BFS speech 119 0.948 0.907 0.988 <0.001 ≥14.0 0.891 0.873 0.917 0.939 0.830
CNS-BFS swallowing 113 0.830 0.756 0.905 <0.001 ≥16.0 0.770 0.690 0.855 0.833 0.723
CNS-BFS sialorrhea 120 0.884 0.825 0.942 <0.001 ≥11.0 0.775 0.469 0.986 0.958 0.729
ALSFRS-R total score 111 0.603 0.496 0.710 0.059 ≤32.0 0.559 0.732 0.457 0.441 0.744
ALSFRS-R bulbar subscore 111 0.922 0.874 0.970 <0.001 ≤9.0 0.856 0.919 0.776 0.838 0.884
ALSFRS-R 1. Speech 118 0.916 0.872 0.960 <0.001 ≤2.0 0.814 0.978 0.712 0.677 0.981
ALSFRS-R 3. Swallowing 112 0.696 0.607 0.786 <0.001 ≤3.0 0.652 0.559 0.795 0.809 0.538
ALSFRS-R 2. Salivation 119 0.827 0.755 0.899 <0.001 ≤3.0 0.597 0.324 1.000 1.000 0.500
VAS speech 117 0.862 0.792 0.933 <0.001 ≤7.0 0.803 0.841 0.759 0.803 0.804
VAS swallowing 112 0.710 0.614 0.807 <0.001 ≤8.0 0.679 0.620 0.726 0.646 0.703
VAS sialorrhea 118 0.854 0.786 0.921 <0.001 ≤8.0 0.754 0.447 0.958 0.875 0.723
Timed reading (words/min) 117 0.917 0.867 0.968 <0.001 ≤149.3 0.863 0.877 0.846 0.877 0.846
Timed swallowing: solids 113 0.762 0.674 0.851 <0.001 ≥11.2 0.699 0.603 0.844 0.854 0.585
Timed swallowing: water 113 0.760 0.674 0.847 <0.001 ≥5.0 0.717 0.682 0.739 0.625 0.785
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; AUC, area under the curve; CNS-BFS, Center for Neurologic
Study Bulbar Function Scale; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver-operating characteristic; VAS,
visual analog scale.
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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Table 2 Operating characteristics for prediction of any physician diagnosis of bulbar dysfunction by Center for Neurologic Study Bulbar Func-





















21 69 43 0 0 100.0 0.0 61.6 61.6
22 68 32 11 1 98.6 25.6 70.5 68.0 91.7
23 68 27 16 1 98.6 37.2 75.0 71.6 94.1
24 68 25 18 1 98.6 41.9 76.8 73.1 94.7
25 68 23 20 1 98.6 46.5 78.6 74.7 95.2
27 68 20 23 1 98.6 53.5 81.3 77.3 95.8
28 68 18 25 1 98.6 58.1 83.0 79.1 96.2
29 68 16 27 1 98.6 62.8 84.8 81.0 96.4
30 68 15 28 1 98.6 65.1 85.7 81.9 96.6
31 65 14 29 4 94.2 67.4 83.9 82.3 87.9
32 64 14 29 5 92.8 67.4 83.0 82.1 85.3
33 64 12 31 5 92.8 72.1 84.8 84.2 86.1
34 64 10 33 5 92.8 76.7 86.6 86.5 86.8
35 64 7 36 5 92.8 83.7 89.3 90.1 87.8
36 64 6 37 5 92.8 86.0 90.2 91.4 88.1
37 64 4 39 5 92.8 90.7 92.0 94.1 88.6
39 63 3 40 6 91.3 93.0 92.0 95.5 87.0
41 61 2 41 8 88.4 95.3 91.1 96.8 83.7
42 58 2 41 11 84.1 95.3 88.4 96.7 78.8
43 58 1 42 11 84.1 97.7 89.3 98.3 79.2
44 57 1 42 12 82.6 97.7 88.4 98.3 77.8
45 56 1 42 13 81.2 97.7 87.5 98.2 76.4
46 54 1 42 15 78.3 97.7 85.7 98.2 73.7
47 51 1 42 18 73.9 97.7 83.0 98.1 70.0
48 50 1 42 19 72.5 97.7 82.1 98.0 68.9
49 47 1 42 22 68.1 97.7 79.5 97.9 65.6
50 45 1 42 24 65.2 97.7 77.7 97.8 63.6
51 44 1 42 25 63.8 97.7 76.8 97.8 62.7
52 39 1 42 30 56.5 97.7 72.3 97.5 58.3
53 37 1 42 32 53.6 97.7 70.5 97.4 56.8
54 35 1 42 34 50.7 97.7 68.8 97.2 55.3
55 32 1 42 37 46.4 97.7 66.1 97.0 53.2
56 32 0 43 37 46.4 100.0 67.0 100.0 53.8
57 27 0 43 42 39.1 100.0 62.5 100.0 50.6
58 26 0 43 43 37.7 100.0 61.6 100.0 50.0
59 24 0 43 45 34.8 100.0 59.8 100.0 48.9
60 23 0 43 46 33.3 100.0 58.9 100.0 48.3
61 22 0 43 47 31.9 100.0 58.0 100.0 47.8
62 21 0 43 48 30.4 100.0 57.1 100.0 47.3
64 18 0 43 51 26.1 100.0 54.5 100.0 45.7
65 16 0 43 53 23.2 100.0 52.7 100.0 44.8
66 15 0 43 54 21.7 100.0 51.8 100.0 44.3
67 14 0 43 55 20.3 100.0 50.9 100.0 43.9
69 13 0 43 56 18.8 100.0 50.0 100.0 43.4
70 12 0 43 57 17.4 100.0 49.1 100.0 43.0
71 11 0 43 58 15.9 100.0 48.2 100.0 42.6
72 10 0 43 59 14.5 100.0 47.3 100.0 42.2
73 8 0 43 61 11.6 100.0 45.5 100.0 41.3
75 6 0 43 63 8.7 100.0 43.8 100.0 40.6
80 5 0 43 64 7.2 100.0 42.9 100.0 40.2
84 4 0 43 65 5.8 100.0 42.0 100.0 39.8
85 3 0 43 66 4.3 100.0 41.1 100.0 39.4
94 2 0 43 67 2.9 100.0 40.2 100.0 39.1
110 1 0 43 68 1.4 100.0 39.3 100.0 38.7
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Table 3 Construct validity: correlations between individual measures of bulbar impairment at baseline and from baseline to visit 1
Baseline only Baseline to visit 1
Measure 1 Measure 2 n Correlation P-value n Correlation P-value
CNS-BFS total ALSFRS-R total score 119 0.254 0.005 57 0.400 0.002
CNS-BFS total ALSFRS-R bulbar subscore 119 0.896 <0.001 57 0.388 0.002
CNS-BFS total ALSFRS-R fine motor subscore 119 0.059 0.523 57 0.192 0.149
CNS-BFS total ALSFRS-R gross motor subscore 119 0.127 0.167 57 0.083 0.535
CNS-BFS total ALSFRS-R respiratory subscore 119 0.117 0.202 57 0.236 0.075
CNS-BFS speech ALSFRS-R 1. Speech 119 0.882 <0.001 57 0.495 <0.001
CNS-BFS swallowing ALSFRS-R 3. Swallowing 119 0.762 <0.001 57 0.182 0.173
CNS-BFS sialorrhea ALSFRS-R 2. Salivation 119 0.723 <0.001 57 0.111 0.410
CNS-BFS speech VAS speech self-assessment 118 0.758 <0.001 58 0.339 0.008
CNS-BFS swallowing VAS swallowing self-assessment 118 0.538 <0.001 58 0.027 0.840
CNS-BFS sialorrhea VAS sialorrhea self-assessment 118 0.674 <0.001 58 0.153 0.247
ALSFRS-R 1. Speech VAS speech self-assessment 117 0.730 <0.001 57 0.131 0.329
ALSFRS-R 3. Swallowing VAS swallowing self-assessment 117 0.392 <0.001 57 0.046 0.731
ALSFRS-R 2. Salivation VAS sialorrhea self-assessment 117 0.567 <0.001 57 0.112 0.404
CNS-BFS speech Timed reading 117 0.762 <0.001 57 0.269 0.041
CNS-BFS swallowing Timed swallowing: solids 120 0.519 <0.001 57 0.086 0.522
CNS-BFS swallowing Timed swallowing: water 120 0.519 <0.001 57 0.109 0.417
ALSFRS-R 1. Speech Timed reading 116 0.722 <0.001 56 0.411 0.001
ALSFRS-R 3. Swallowing Timed swallowing: solids 119 0.376 <0.001 56 0.142 0.295
ALSFRS-R 3. Swallowing Timed swallowing: water 119 0.481 <0.001 56 0.195 0.146
VAS speech self-assessment Timed reading 115 0.627 <0.001 57 0.149 0.266
VAS swallowing self-assessment Timed swallowing: solids 118 0.412 <0.001 57 0.138 0.304
VAS swallowing self-assessment Timed swallowing: water 118 0.309 <0.001 57 0.054 0.686
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; CNS-BFS, Center for Neurologic Study Bulbar Function Scale;
VAS, visual analog scale.
Table 4 Estimates of natural rates of progression




a Baseline to visit 3 1.164 0.531 0.099 2.228
CNS-BFS speech Baseline to visit 3 0.541 0.245 0.050 1.033
CNS-BFS swallowing Baseline to visit 3 0.033 0.259 0.485 0.552
CNS-BFS sialorrhea Baseline to visit 3 0.634 0.263 0.107 1.162
CNS-LS total score Baseline to visit 3 0.338 0.252 0.167 0.843
ALSFRS-R total scorea Baseline to visit 3 1.124 0.239 1.602 0.646
ALSFRS-R bulbar subscore
a Baseline to visit 3 0.383 0.105 0.593 0.173
ALSFRS-R fine motor subscore Baseline to visit 3 0.252 0.100 0.452 0.052
ALSFRS-R gross motor subscore Baseline to visit 3 0.175 0.084 0.343 0.007
ALSFRS-R respiratory subscore Baseline to visit 3 0.249 0.096 0.441 0.057
ALSFRS-R 1. Speech Baseline to visit 3 0.159 0.041 0.242 0.076
ALSFRS-R 2. Salivation Baseline to visit 3 0.173 0.075 0.322 0.023
ALSFRS-R 3. Swallowing Baseline to visit 3 0.049 0.043 0.135 0.037
VAS speech self-assessment Baseline to visit 3 0.455 0.151 0.759 0.152
VAS swallowing self-assessment Baseline to visit 3 0.327 0.185 0.699 0.044
VAS sialorrhea self-assessment Baseline to visit 3 0.312 0.185 0.682 0.059
Timed reading test: words/min Baseline to visit 3 2.817 1.127 5.075 0.560
Timed swallowing test: solids Baseline to visit 3 0.583 0.639 1.863 0.698
Timed swallowing test: water Baseline to visit 3 1.004 0.673 0.345 2.353
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; CNS-BFS, Center for Neurologic Study Bulbar Function Scale;
CNS-LS, CNS Lability Scale; SE, standard error; VAS, visual analog scale. aThe CNS-BFS total score refers to the score for all 21 questions
in the CNS-BFS scale (seven questions each in the speech, swallowing, and sialorrhea domains); the ALSFRS-R total score includes 12 ques-
tions, while the ALSFRS-R bulbar subscore includes three questions addressing separate aspects of bulbar function (speech, swallowing and
salivation).
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outperforms both the bulbar component of the
ALSFRS-R and bulbar VASs when correlations are
made between these scales and timed reading and
swallowing. Based on these findings and its ease of
administration, we feel that the CNS-BFS is a useful
metric for assessing bulbar function in patients with
ALS in a research or clinical setting. Longer studies,
perhaps extending over a year or more, need to be
undertaken to fully understand the behavior of the
CNS-BFS over time, as well as more recently inves-
tigated measures, such as pause and speech rates
[21]. However, the 10-week serial data reported in
this study should be sufficient to provide guidance
for an upcoming 12-week treatment trial that will
assess the effect of Nuedexta on bulbar impairment
in ALS.
Is this relevant and useful information? One of the
strengths of this study is that it affirms patients’
insights into their condition. For example, the swal-
lowing domain of the CNS-BFS addresses self-
reported feeding behavior and, as noted above, the
CNS-BFS was well correlated with clinician diagnosis
of impaired swallowing and two timed measures of
swallowing. Moreover, it is noteworthy that, in the
instance of the recently completed Nuedexta treatment
trial [15], both the CNS-BFS and ALSFRS-R were
sensitive indicators of a treatment response, whereas
traditionally applied measures, such as timed speech
and swallowing, were less responsive. In essence, had
this trial relied solely on timed measures, it would
have failed due to a type 2 statistical error.
Historically, the Food and Drug Administration
has been reluctant to place emphasis on patient self-
assessment scales. The patient’s perception of their ill-
ness has not attained the stature that has been attribu-
ted to traditionally objective measures, such as timed
speech, in the research community. Historical objec-
tions to this type of information have included the
possibility of lengthy questionnaires not being com-
pleted and that patient attention could be impaired
because of health issues and the concomitant use of
medications. It is refreshing to note that recent Food
and Drug Administration guidelines have given more
credence to self-report measures [22].
The above-mentioned clinical trial also provided a
unique opportunity to determine which measures best
interrogated the various bulbar functions as determined
by their response to therapy. The CNS-BFS total score
performed well in detecting treatment response to Nue-
dexta, but it is not certain that other drugs would have
the same effect. We have not, as yet, confirmed that the
psychometric properties of the CNS-BFS are ideal.
These properties might be optimized through applica-
tion of modern item-response theory with development
of an abbreviated scale and one that better separates the
underlying factors. A revision of the ALSFRS-R has
recently been recommended based on the use of similar
clinimetric methodology [23].
Based on the imperfections inherent in the measure-
ment of bulbar function, considerable effort is cur-
rently being devoted to the development of ‘objective’
measures of bulbar function. Examples of this include
work demonstrating that speech and pause rates may
be useful markers for monitoring longitudinal change
[21]. While these and additional objective measures
are needed, our data suggest that patient self-assess-
ment scales are well suited for continued evaluation of
the complex and nuanced features of bulbar function
and thus useful in both clinical and research settings.
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